followed by a sharp endotherm at 266 u00b0 c the typical dsc thermogram is shown in fig2 according to another aspect of the present invention a process is provided for the preparation of crystalline solid eprosartan acetate which comprises a dissolving crude eprosartan free base in acetic acid b adding methylene chloride slowly to the solution obtained in step a at a temperature below about 40 u00b0 c and c collecting the precipitated eprosartan acetate crystalline solid the purity measured by hplc of the eprosartan acetate obtained according to the present invention is preferably about above 99 more preferably about above 99 5 and still more preferably about above 99 9 crude eprosartan free base used as starting material may be used in the form of a residue or a crystalline form obtained by processes described in the art the term u2018 crude eprosartan free base u2019 in the specification refers to eprosartan free base having hplc purity below 98 5 preferably the crude eprosartan free base in step a may be dissolved in acetic acid at a temperature above about 40 u00b0 c more preferably at a temperature between 45 u00b0 c and 110 u00b0 c and still more preferably at a temperature between 50 u00b0 c and 100 u00b0 c the solution obtained in step a may optionally be subjected to carbon treatment and then used in the next step preferably methylene chloride may be added to the filtrate in step b at a temperature between 0 u00b0 c and 40 u00b0 c more preferably at a temperature between 10 u00b0 c and 40 u00b0 c.